Citations

Clear

6273 citation(s) found for "To, Andrew".

The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs, Jeremy W. , Stanek, C , Symeonidis, Argiris , Shih, Andrew W. , Gavriilaki, Eleni , Pavenski, Katerina , Moorehead, Amy , Mingot‐Castellano, María Eva , Daou, Laetitia , Arnold, Donald M. , Henrie, Ryan , Smith, Tyler , Sreenivasan, Gayatri , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Harrington, Thomas J., Byrnes, Diana M. , Bitsani, Aikaterini , Davis, Amanda K. , Robinson, Danielle H., Eichbaum, Quentin , Kaiafa, Georgia , Klapper, Ellen, Klein, Monica S., Kotsiou, Nikolaos , Lalayanni, Chrysavgi , Mandala, Evdokia , Alkhateb, Rahaf, Fortuny, Lisandro, Mellios, Zois, Papalexandri, Apostolia, Parsons, Meredith G , Wellard, Cameron , Jia, Shiyang , Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bouzid, Raïda , Coppo, Paul, Bloch, Evan M. , Adkins, Brian D. , Stanek, Caroline G , Booth, Garrett , Symeonidis, Argiris , Shih, Andrew W , Gavriilaki, Eleni , Moorehead, Amy , Peyvandi, Flora , Mancini, Ilaria , Raval, Jay S , Mingot-Castellano, Maria Eva , Crowe, Elizabeth P , Arnold, Donald M , Yamada, Chisa , Kotsiou, Nikolaos , Aldarweesh, Fatima , Schlueter, Annette J , Tormey, Christopher A , Wood, Erica M , Wheeler, Allison P , Yates, Sean G , Bloch, Evan M , Adkins, Brian David , Jacobs, Jeremy W , Parsons, Meredith G , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Pavenski, Katerina , Peyvandi, Flora , Agosti, Pasquale , Stephens, Laura D. , Raval, Jay S. , Pai, Menaka , Marques, Marisa B. , Yamada, Chisa , Robinson, Danielle H. , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Kapsali, Eleni , Perez-Alvarez, Ingrid , Aldarweesh, Fatima , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Coppo, Paul

Mayo Clinic

American Journal of Hematology | August 13, 2024 | Volume: 99 | Issue: 11 | Pages: 2063-2074

10.1002/ajh.27458 | PMID 39136282 Get It

AbstractPrior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes have diminished the ability to perform a rigorous assessment. This 5‐year retrospective study assessed the epidemiology of iTTP and determined whether it displays a seasonal pattern. Patients with both initial and relapsed iTTP (defined as a disintegrin and metalloprotease with thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada, France, Greece, Italy, Spain, and the US were included. Seasons were defined as: Northern Hemisphere—winter (December–February); spring (March–May); summer (June–August); autumn (September–November) and Southern Hemisphere—winter (June–August); spring (September–November); summer (December–February); autumn (March–May). Additional outcomes included the mean temperature in months with and without an iTTP episode at each site. A total of 583 patients experienced 719 iTTP episodes. The observed proportion of iTTP episodes during the winter was significantly greater than expected if equally distributed across seasons (28.5%, 205/719, 25.3%–31.9%; p = .03). Distance from the equator and mean temperature deviation both positively correlated with the proportion of iTTP episodes during winter. Acute iTTP episodes were associated with the winter season and colder temperatures, with a second peak during summer. Occurrence during winter was most pronounced at sites further from the equator and/or with greater annual temperature deviations. Understanding the etiologies underlying seasonal patterns of disease may assist in discovery and development of future preventative therapies and inform models for resource utilization.
Neuro-Ophthalmic Literature Review
Bellows, David A., Chen, John J. , Hung, Wei-Che , Vaphiades, Michael S., Chen, John J , Mak, Andrew C. Y. , McClelland, Collin M. , Verma, Rashmi , Zhang, Xiaojun

Mayo Clinic

Neuro-Ophthalmology | August 12, 2024 | Volume: 48 | Issue: 5 | Pages: 381-389

10.1080/01658107.2024.2384339 Get It

ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam comb
Jacobs, Michael R. , Abdelhamed, Ayman M., Good, Caryn E., Mack, Andrew R , Bethel, Christopher R. , Marshall, Steven H. , Hujer, Andrea M. , Hujer, Kristine M., Patel, Robin , Fowler, Vance G. , Rhoads, Daniel D. , Six, David A. , Uehara, Tsuyoshi , Papp‐Wallace, Krisztina M. , van Duin, David , Rhoads, Daniel D , Six, David A , Moeck, Greg , Uehara, Tsuyoshi , Papp-Wallace, Krisztina M , Bonomo, Robert A , Patel, Robin , Fowler, Vance G. , Bonomo, Robert A.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | August 12, 2024 | Volume: 68 | Issue: 9 | Pages: No page available

10.1128/aac.00751-24 | PMID 39133021 Get It

ABSTRACT Taniborbactam, a bicyclic boronate β-lactamase inhibitor with activity against Klebsiella pneumoniae carbapenemase (KPC), Verona integron–encoded metallo-β-lactamase (VIM), New Delhi metallo-β-lactamase (NDM), extended-spectrum beta-lactamases (ESBLs), OXA-48, and AmpC β-lactamases, is under clinical development in combination with cefepime. Susceptibility of 200 previously characterized carbapenem-resistant K. pneumoniae and 197 multidrug-resistant (MDR) Pseudomonas aeruginosa to cefepime-taniborbactam and comparators was determined by broth microdilution. For K. pneumoniae (192 KPC; 7 OXA-48-related), MIC 90 values of β-lactam components for cefepime-taniborbactam, ceftazidime-avibactam, and meropenem-vaborbactam were 2, 2, and 1 mg/L, respectively. For cefepime-taniborbactam, 100% and 99.5% of isolates of K. pneumoniae were inhibited at ≤16 mg/L and ≤8 mg/L, respectively, while 98.0% and 95.5% of isolates were susceptible to ceftazidime-avibactam and meropenem-vaborbactam, respectively. For P. aeruginosa , MIC 90 values of β-lactam components of cefepime-taniborbactam, ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem-vaborbactam were 16, >8, >8, and >4 mg/L, respectively. Of 89 carbapenem-susceptible isolates, 100% were susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and cefepime-taniborbactam at ≤8 mg/L. Of 73 carbapenem-intermediate/resistant P. aeruginosa isolates without carbapenemases, 87.7% were susceptible to ceftolozane-tazobactam, 79.5% to ceftazidime-avibactam, and 95.9% and 83.6% to cefepime-taniborbactam at ≤16 mg/L and ≤8 mg/L, respectively. Cefepime-taniborbactam at ≤16 mg/L and ≤8 mg/L, respectively, was active against 73.3% and 46.7% of 15 VIM- and 60.0% and 35.0% of 20 KPC-producing P. aeruginosa isolates. Of all 108 carbapenem-intermediate/resistant P. aeruginosa isolates, cefepime-taniborbactam was active against 86.1% and 69.4% at ≤16 mg/L and ≤8 mg/L, respectively, compared to 59.3% for ceftolozane-tazobactam and 63.0% for ceftazidime-avibactam. Cefepime-taniborbactam had in vitro activity comparable to ceftazidime-avibactam and greater than meropenem-vaborbactam against carbapenem-resistant K. pneumoniae and carbapenem-intermediate/resistant MDR P. aeruginosa .
Creation of a predictive calculator to determine adequacy of occlusion of the woven endobridge (WEB) device in intracranial aneurysms—A retrospective analysis of the WorldWide WEB Consortium database
Musmar, Basel , Adeeb, Nimer , Gendreau, Julian , Horowitz, Melanie Alfonzo , Salim, Hamza , Sanmugananthan, Praveen , Aslan, Assala , Cancelliere, Nicole M , McLellan, Rachel , Şenol, Yiğit Can , Lay, Sovann V. , Guenego, Adrien , Renieri, Leonardo, Naamani, Kareem El, Premat, Kévin , Möhlenbruch, Markus, Kral, Michael , Doron, Omer , Salem, Mohamed M , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza , Župančić, Vedran , Tutino, Vincent M. , Gokhan, Yuce, İmamoğlu, Çetin , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M, Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Diestro, Jose Danilo Bengzon , Pukenas, Bryan , Burkhardt, Jan‐Karl , Martinez-Gutierrez, Juan Carlos, Essibayi, Muhammed Amir , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S., Pero, Guglielmo , Nossek, Erez , Raz, Eytan , Killer-Oberfalzer, Monika, Asadi, Hamed , Brook, Allan , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter, Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Bydon, Mohamad , Patel, Aman B. , Salim, Hamza , Algin, Oktay , Ghozy, Sherief , Dibas, Mahmoud , Senol, Yigit Can , Guenego, Adrien , Tjoumakaris, Stavropoula , Shotar, Eimad , Lylyk, Ivan , Foreman, Paul M , Shaikh, Hamza A , Župančić, Vedran , Hafeez, Muhammad U , Ren, Yifan , Schirmer, Clemens M , Hassan, Ameer E , Nguyen, Anh , Jones, Jesse , Ulfert, Christian , Essibayi, Muhammed Amir , Tawk, Rabih, Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J , Siddiqui, Adnan H , Altschul, David J , Regenhardt, Robert W , Limbucci, Nicola , Cuellar-Saenz, Hugo H , Dmytriw, Adam A , Diestro, Jose Danilo B , Tutino, Vincent M , Kalousek, Vladimir , Musmar, Basel , Cancelliere, Nicole M , Lay, Sovann V , Burkhardt, Jan‐Karl , Brown, Nolan J. , Ghozy, Sherief , Dibas, Mahmoud , Orscelik, Atakan , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Möhlenbruch, Markus , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Bayrak, Ahmet , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Tawk, Rabih G. , Panni, Pietro , Puri, Ajit S , Griessenauer, Christoph J. , Siddiqui, Adnan H. , Aziz‐Sultan, Mohammad Ali , Limbucci, Nicola , Hasan, David , Cuellar, Hugo , Jabbour, Pascal , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Interventional Neuroradiology | August 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241267320 | PMID 39127463 Get It

Background Endovascular treatment with the woven endobridge (WEB) device has been widely utilized for managing intracranial aneurysms. However, predicting the probability of achieving adequate occlusion (Raymond–Roy classification 1 or 2) remains challenging. Objective Our study sought to develop and validate a predictive calculator for adequate occlusion using the WEB device via data from a large multi-institutional retrospective cohort. Methods We used data from the WorldWide WEB Consortium, encompassing 356 patients from 30 centers across North America, South America, and Europe. Bivariate and multivariate regression analyses were performed on a variety of demographic and clinical factors, from which predictive factors were selected. Calibration and validation were conducted, with variance inflation factor (VIF) parameters checked for collinearity. Results A total of 356 patients were included: 124 (34.8%) were male, 108 (30.3%) were elderly (≥65 years), and 118 (33.1%) were current smokers. Mean maximum aneurysm diameter was 7.09 mm (SD 2.71), with 112 (31.5%) having a daughter sac. In the multivariate regression, increasing aneurysm neck size (OR 0.706 [95% CI: 0.535–0.929], p = 0.13) and partial aneurysm thrombosis (OR 0.135 [95% CI: 0.024–0.681], p = 0.016) were found to be the only statistically significant variables associated with poorer likelihood of achieving occlusion. The predictive calculator shows a c-statistic of 0.744. Hosmer–Lemeshow goodness-of-fit test indicated a satisfactory model fit with a p-value of 0.431. The calculator is available at: https://neurodx.shinyapps.io/WEBDEVICE/ . Conclusion The predictive calculator offers a substantial contribution to the clinical toolkit for estimating the likelihood of adequate intracranial aneurysm occlusion by WEB device embolization.
Immune Effector Cell-Associated Enterocolitis following Chimeric Antigen Receptor T-cell Therapy in Multiple Myeloma
Song, Jinming , Lekakis, Lazaros J. , Samraj, Annie N. , Naresh, Kikkeri N. , Vazquez‐Martinez, Mariola , Mikkilineni, Lekha , Corraes, Andre De Menezes Silva , Kalariya, Nilesh, Patel, Krina K. , Ferreri, Christopher J. , Voorhees, Peter M. , Valdes, Cesar Rodriguez , Cowan, Andrew J., Sborov, Douglas W. , Lin, Yi, Naresh, Kikkeri N , Fortuna, Gliceida Galarza , Banerjee, Rahul , Fernandez‐Pol, Sebastian , Baz, Rachid , Spiegel, Jay Y. , Gubatan, John , Sidana, Surbhi , Shim, Kevin G. , Fonseca, Rafaël , Richard, Shambavi , Hansen, Doris K. , Wang, Yinghong

Mayo Clinic

No container title available | August 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4727434/v1 Get It

Abstract Background: Several immune effector cell (IEC) therapies have been approved for multiple myeloma (MM), including chimeric antigen receptor T-cell (CAR-T) therapies such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). We report 14 cases of IEC-associated enterocolitis, in five cases fatal, following CAR-T therapy in MM. Methods: We performed a retrospective analysis of cases of diarrhea, enterocolitis, or colitis following commercial ide-cel or cilta-cel (including out-of-specification products) at 10 centers within the United States Myeloma Immunotherapy Consortium. Patients were treated according to the local standard of care at each participating center. Results: We identified 14 cases of IEC-associated enterocolitis out of 1159 CAR-T infusions, corresponding to a 1.2% incidence (0.2% for ide-cel and 2.3% for cilta-cel). This proportion excludes 3 cases of potential or confirmed T-cell lymphoproliferative disorders of the bowel. Patients developed acute-onset symptoms (typically non-bloody Grade 3+ diarrhea) with negative infectious workup beginning a median of 79 days (range: 22-210 days) after CAR-T therapy and a median of 74 days after cytokine release syndrome resolution (range: 2-202 days). Biopsies uniformly demonstrated inflammation, with specific findings including intra-epithelial lymphocytosis, crypt dropout on colon biopsies, and villous blunting on duodenal biopsies. Systemic corticosteroids were initiated in 10 patients (71%) a median of 26 days (range: 1-80 days) following symptom onset. Only 40% of steroid-treated patients had symptomatic improvement; subsequent infliximab or vedolizumab led to improvement in 50% and 33% of corticosteroid-refractory patients, respectively. With a median follow-up of 224 days, n = 4 have had diarrhea resolution, n = 5 have had improved or stable symptoms, and n = 5 (36%) have died from IEC-associated enterocolitis or treatment-emergent infections. Conclusions: IEC-associated enterocolitis is a distinct but rare complication of CAR-T therapy characterized by non-bloody diarrhea typically beginning 1-3 months after infusion. Thorough diagnostic workup (including evaluation for potential T-cell malignancies) and appropriate management with an expert gastroenterologist are essential. Further research is critical to understand the pathogenesis of this novel toxicity. In the interim, the early use of infliximab or vedolizumab may potentially hasten symptom resolution and lower reliance on high-dose corticosteroids during the post-CAR-T period.
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia
Chang, Ti‐Cheng , Chen, Wenan , Cheng, Zhongshan , Hedges, Dale J., Elsayed, Abdelrahman , Pounds, Stanley , Shago, Mary , Rabin, Karen R. , Raetz, Elizabeth A. , Cheng, Cheng , Angiolillo, Anne , Baviskar, Pradyuamna , Borowitz, Michael J., Carroll, Andrew J. , Carroll, William L. , Heerema, Nyla A. , Larsen, Eric , Mattano, Leonard A. , Maloney, Kelly W. , Ramirez, Nilsa C. , Salzer, Wanda L. , Wu, Gang , Loh, Mignon L. , Wu, Gang , Rabin, Karen R , Raetz, Elizabeth A , Devidas, Meenakshi , Baviskar, Pradyuamna , Burke, Michael J , Carroll, Andrew J , Harvey, Richard , Iacobucci, Ilaria , Wang, Jeremy R , Jeha, Sima , Mattano, Leonard A , Maloney, Kelly W , Pui, Ching-Hon , Ramirez, Nilsa C , Willman, Cheryl , Wood, Brent L , Hunger, Stephen P , Mullighan, Charles G , Loh, Mignon L , Pounds, Stanley B , Wu, Gang , Qu, Chunxu , Devidas, Meenakshi , Chen, I‐Ming , Harvey, Richard C. , Iacobucci, Ilaria , Wang, Jeremy , Willman, Cheryl L. , Winick, Naomi Joan , Wood, Brent L. , Hunger, Stephen P. , Mullighan, Charles G.

Mayo Clinic

Journal of Clinical Oncology | August 9, 2024 | Volume: 42 | Issue: 29 | Pages: 3491-3503

10.1200/jco.23.02238 | PMID 39121442 Get It

PURPOSE Although cure rates for childhood acute lymphoblastic leukemia (ALL) exceed 90%, ALL remains a leading cause of cancer death in children. Half of relapses arise in children initially classified with standard-risk (SR) disease. MATERIALS AND METHODS To identify genomic determinants of relapse in children with SR ALL, we performed genome and transcriptome sequencing of diagnostic and remission samples of children with SR (n = 1,381) or high-risk B-ALL with favorable cytogenetic features (n = 115) enrolled on Children's Oncology Group trials. We used a case-control study design analyzing 439 patients who relapsed and 1,057 who remained in complete remission for at least 5 years. RESULTS Genomic subtype was associated with relapse, which occurred in approximately 50% of cases of PAX5 -altered ALL (odds ratio [OR], 3.31 [95% CI, 2.17 to 5.03]; P = 3.18 × 10 –8 ). Within high-hyperdiploid ALL, gain of chromosome 10 with disomy of chromosome 7 was associated with favorable outcome (OR, 0.27 [95% CI, 0.17 to 0.42]; P = 8.02 × 10 –10 ; St Jude Children's Research Hospital validation cohort: OR, 0.22 [95% CI, 0.05 to 0.80]; P = .009), and disomy of chromosomes 10 and 17 with gain of chromosome 6 was associated with relapse (OR, 7.16 [95% CI, 2.63 to 21.51]; P = 2.19 × 10 –5 ; validation cohort: OR, 21.32 [95% CI, 3.62 to 119.30]; P = .0004). Genomic alterations were associated with relapse in a subtype-dependent manner, including alterations of INO80 in ETV6::RUNX1 ALL, IKZF1 , and CREBBP in high-hyperdiploid ALL and FHIT in BCR::ABL1 -like ALL. Genomic alterations were also associated with the presence of minimal residual disease, including NRAS and CREBBP in high-hyperdiploid ALL. CONCLUSION Genetic subtype, patterns of aneuploidy, and secondary genomic alterations determine risk of relapse in childhood ALL. Comprehensive genomic analysis is required for optimal risk stratification.
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Tefferi, Ayalew , Barosi, Giovanni , Hernández‐Boluda, Juan Carlos , Bose, Prithviraj , Döhner, Konstanze , Gangat, Naseema , Garcia, Jacqueline S. , Gisslinger, Heinz , Gupta, Vikas , Harrison, Claire , Loscocco, Giuseppe Gaetano , Mora, Barbara , Odenike, Olatoyosi, Pardanani, Animesh , Patel, Anand , Pemmaraju, Naveen , Rampal, Raajit K. , Sirhan, Shireen , Vachhani, Pankit , Vannucchi, Alessandro M., Barbui, Tiziano , Hernández-Boluda, Juan Carlos , Bose, Prithviraj , Gangat, Naseema , Garcia, Jacqueline S , Gupta, Vikas , Hexner, Elizabeth , Hobbs, Gabriela S , Koschmieder, Steffen , Kuykendall, Andrew , Loscocco, Giuseppe Gaetano , Mascarenhas, John , Masarova, Lucia , Mesa, Ruben , Oh, Stephen T , Patel, Anand , Pemmaraju, Naveen , Rambaldi, Alessandro , Szuber, Natasha , Vachhani, Pankit , Barbui, Tiziano , Passamonti, Francesco , Ellis, Martin H. , Gotlib, Jason , Guglielmelli, Paola , Hexner, Elizabeth O. , Hobbs, Gabriela , Kiladjian, Jean‐Jacques , Koschmieder, Steffen , Kröger, Nicolaus , Mascarenhas, John , Masárová, Lucia , Mesa, Ruben A. , Odenike, Olatoyosi , Oh, Stephen T. , Rambaldi, Alessandro , Szuber, Natasha , Talpaz, Moshe

Mayo Clinic

Blood | August 8, 2024 | Volume: 144 | Issue: 17 | Pages: 1813-1820

10.1182/blood.2024025802 | PMID 39116296 Get It

Abstract With emerging new drugs in myelofibrosis (MF), a robust and harmonized framework for defining the severity of anemia and response to treatment will enhance clinical investigation and facilitate interstudy comparisons. Accordingly, the lead authors on the 2013 edition of the International Working Group–European LeukemiaNet (IWG-ELN) response criteria in MF were summoned to revise their document with the intent to (1) account for gender-specific differences in determining hemoglobin levels for eligibility criteria; (2) revise the definition of transfusion-dependent anemia (TDA) based on current restrictive transfusion practices; and (3) provide a structurally simple and easy to apply response criteria that are sensitive enough to detect efficacy signals (minor response) and also account for major responses. The initial draft of the 2024 IWG-ELN proposed criteria was subsequently circulated around a wider group of international experts and their feedback incorporated. The proposed articles include new definitions for TDA (≥3 units in the 12 weeks before study enrollment) and hemoglobin thresholds for eligibility criteria (&lt;10 g/dL for women and &lt;11 g/dL for men). The revised document also provides separate (TDA vs non-TDA) and graded (major vs minor response) response criteria while preserving the requirement for a 12-week period of screening and observation on treatment.
Patterns and Outcomes of Opioid Use Before and After Hospitalization for Critical Illness: A Population-Based Cohort Study
Henry, Nicole , Warner, Matthew A. , Hanson, Andrew C. , Schulte, Phillip J. , Henry, Nicole R, Warner, Matthew A , Warner, Nafisseh S.

Mayo Clinic

Journal of Intensive Care Medicine | August 6, 2024 | Volume: 40 | Issue: 1 | Pages: 85-93

10.1177/08850666241268473 | PMID 39105427 Get It

Background: Hospitalization represents a major access point for prescription opioids, yet little is known regarding patterns and outcomes of opioid exposures before and after hospitalization for critical illness. Methods: This is an observational, population-based cohort study of adults (≥18 years) hospitalized for critical illness from 2010 to 2019. Multivariable models assess associations between opioid exposures prior to hospitalization, classified according to the Consortium to Study Opioid Risks and Trends, and posthospitalization opioid exposures and clinical outcomes through 1-year posthospitalization. Results: Of 11 496 patients, 6318 (55%) were men with a median age of 66 (51, 79) years and 40% (n = 4623) surgical admissions. Prehospitalization opioid availability included 8449 (73%) none, 2117 (18%) short-term, 471 (4%) episodic, and 459 (4%) long-term. Thirty-nine percent (4144/10 708) of hospital survivors were discharged with opioids, with higher prescribing rates for surgical admissions (55%). Greater preadmission opioid exposures were associated with higher prevalent opioid availability at 1 year (odds ratio [95% confidence interval] 24.1 [18.3-31.8], 9.42 [7.18-12.3], and 2.55 [2.08-3.12] for long-term, episodic, and short-term exposures, respectively, vs none, P < .001). Greater preadmission opioid exposures were associated with longer hospitalizations (1.13 [1.04-1.23], 1.15 [1.06-1.25], and 1.08 [1.04-1.13] multiplicative increase in geometric mean, P < .001), more readmissions (hazard ratio [HR] 2.08 [1.74-2.49], 1.88 [1.56-2.26], and 1.48 [1.33-1.64], P < .001), and higher 1-year mortality (HR 1.59 [1.28-1.98], 1.75 [1.41-2.18], and 1.49 [1.32-1.69], P < .001). Similar associations were observed across surgical and nonsurgical admissions. Conclusions: Prehospitalization opioid exposures in survivors of critical illness are associated with clinical outcomes through 1 year and may serve as important prognostic markers.
Using Pre-operative Insulin Dose to Predict Diabetes Remission After Roux-En-Y Gastric Bypass and Sleeve Gastrectomy
Salameh, Yara , Ghanem, Omar M. , Abi Mosleh, Kamal , Ghanem, Omar M , Ghusn, Wissam , Salameh, Yara , Mosleh, Kamal Abi , Shah, Mithun V , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Surgical Innovation | August 6, 2024 | Volume: 31 | Issue: 5 | Pages: 484-492

10.1177/15533506241273368 | PMID 39105388 Get It

Background Obesity is intricately associated with type-2 diabetes (T2D) and other cardiovascular conditions, increasing morbidity, mortality, and health care costs. Metabolic and bariatric surgeries (MBS) have shown promising results in significant weight loss and T2D remission, but existing predictive scores for post-MBS diabetes remission do not consider insulin dosage, potentially overlooking a critical factor. Methods A retrospective analysis of patients with T2D who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). The study focused on insulin dosage impact, divided into quartiles, on remission rates post-MBS. The effectiveness of RYGB vs SG was compared within insulin dose quartiles with up to 5 years of follow up. Results A total of 508 patients (64% female, 94.9% White, mean age 53.5 ± 10.5 years, BMI (46.0 ± 8.3 kg/m 2 ) were included in the analysis. This study demonstrates a profound association between insulin dosage quartiles and T2D remission after MBS. Patients with lower insulin requirements showed superior remission rates; those in the lowest quartile had remission rates of 73%, 70%, and 62% at 1, 3, and 5 years, respectively, compared to 34%, 37%, and 36% in the highest quartile ( P < 0.001 across all intervals). RYGB surgery showed a significantly better remission in the second and third insulin quartiles, suggesting its effectiveness over SG for patients with mid-range insulin requirements. Conclusion This study underscores the importance of considering insulin dosage when predicting T2D remission post-MBS. The findings advocate for a more nuanced selection of MBS procedures based on individual insulin profiles, potentially enhancing diabetes remission outcomes.
Association between Kidney Stones and CKD
Zhou, Le‐Ting , Ali, Ahmed E. , Jayachandran, Muthuvel , Haskic, Zejfa , Harris, Peter C. , Rule, Andrew D. , Koo, Kevin , Larson, Nicholas B. , Lieske, John C. , Larson, Nicholas B , Lieske, John C , Rule, Andrew D , Harris, Peter C , McDonnell, Shannon K.

Mayo Clinic

Journal of the American Society of Nephrology | August 5, 2024 | Volume: 35 | Issue: 12 | Pages: 1746-1757

10.1681/asn.0000000000000453 | PMID 39102294 Get It

Key Points Common kidney stones are unlikely to be an independent and direct cause of CKD in the general population. CKD may protect against kidney stones because of changes in key urinary factors critical for stone formation. Background Kidney stones and CKD are common disorders with a substantial interaction. Although observational studies have suggested a potential for enhanced CKD risk after prior kidney stones, the exact relationship remains ambiguous. Methods Shared comorbidities between two diseases were identified using unbiased screening. Genome-wide association study summary statistics were obtained from the UK Biobank (UKBB), FinnGen, and CKDGen, followed by genetic association analyses across various traits. Bidirectional Mendelian randomization (MR) analyses were performed to define causal links, complemented by multivariable MR that included the shared comorbidities including hypertension, diabetes, and obesity. Observational analyses were undertaken using cohorts from the Mayo Clinic and a UKBB subset. Results Despite identifying a total of 123 conditions as shared comorbidities, there was no significant genetic correlation between kidney stones and CKD. Unadjusted MR analysis revealed no significant association between kidney stones and CKD risk (UKBB [exposure]/FinnGen [outcome]: odds ratio [OR]=0.97, 95% confidence interval [CI], 0.88 to 1.06; FinnGen/UKBB: OR=1.17, 95% CI, 0.98 to 1.39). Kidney stones did significantly associate with a higher urinary albumin-creatinine ratio ( β =0.014, 95% CI, 0.002 to –0.025), but this association disappeared in the multivariable MR model ( β =0.009, 95% CI, −0.003 to 0.020). Furthermore, in a cross-sectional analysis limited to the UKBB cohort, a robust regression model did not detect an independent association between kidney stones and urinary albumin-creatinine ratio ( β =0.16, 95% CI, −0.04 to 0.35) or eGFR ( β =0.10, 95% CI, −0.07 to 0.28). Conversely, CKD associated with a diminished risk of kidney stones in multivariable MR models (UKBB/FinnGen: OR=0.77, 95% CI, 0.69 to 0.87; FinnGen/UKBB: OR=0.73, 95% CI, 0.66 to 0.81). Furthermore, in the Mayo Clinic cohort with available urinary biochemistries, lower eGFR was associated with lower urinary calcium excretion and urinary calcium oxalate/phosphate supersaturation. Conclusions In this study, kidney stones were not independently associated with CKD. Conversely, CKD was associated with a lower risk of calcium kidney stones likely via changes in key urinary traits, including lower calcium excretion.